1Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphoma with cutaneous manifestations.J Clin Oncol, 1999,17(10) :3117-3121.
2Kurzrock R. Pentostatin (Nipent) in T-cell lymphomas. Semin Oncol, 2000,27(2 Suppl 5):64-66.
3Foss FM. Activity of pentostatin (Nipeat) in cutaneous T-cell lymphoma: single-agent and combination studies. Sermin Oncol,2000,27(2 Suppl 5) :58-63.
4Kuzel TM, Hurria A, Samuelson E, et al. Phase Ⅱ trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood, 1996,87(3):906-911.
5Zinzani PL, Baliva G, Magagnoli M, et al. Gemeitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol, 2000, 18(13) :2603-2606.
6Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol, 2000,18(15):2908- 2925.
7Henney JE. From the Food and Drug Administration. JAMA,2000 ,283(9):1131.
8Jumbou O, N'Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungcides and Sezary syndrome treated by interferonalfa. Br J Dermatol, 1999,140(3):427-431.
9Rook AH, Wood GS, Yoo EK, et al.Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood, 1999,94(3):902-908.
10Marolleau JP, Baceard M, Flageul B,et al. High-dose recombinant inter leukin-2 in advanced cutaneous T-cell lymphoma. Arch Demratol, 1995, 131(5) :574-579.
